Mylan agreed to pay $96.5 million in Provigil antitrust class action

Mylan NV has agreed to pay $96.5 million (£77.5 million) to settle claims by drug purchasers that it delayed launching a generic version of Cephalon Inc's narcolepsy drug Provigil in exchange for payment from Cephalon. The settlement was disclosed in a filing by the drug purchasers in Pennsylvania federal court on Friday, and must still be approved by the court. The money will go to purchasers that bought brand-name Provigil from Cephalon directly, like wholesalers and distributors.